Elevated levels of IL-2 and PDL-1 were significantly associated with favorable clinical responses to ICI therapy, consistent with previous studies linking robust anti-tumor immune response to cytokine-mediated T-cell activation. The gene discussed is IL2; the disease is neoplasm.